NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Shell Companies · USD

GP-Act III Acquisition Corp. (GPAT) Stock Analysis

GP-Act III Acquisition Corp. (GPAT) is a Shell Companies stock listed on NASDAQ and quoted in US Dollar.

GPAT

$10.97

$0.00 (0.00%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare GPAT with… →

GPAT Key Statistics

As of Sep 4, 2026
Trading
Open
$10.97
Previous Close
$10.97
52-Week Range
10.56–12.00
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
−0.00
Valuation
Market Cap
$177.29M
P/E Ratio
43.88
EPS (ttm)Profit attributable to each share over the last twelve months.
0.25
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
$11.89M+37.13%
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
16.16M
1-Year Return
+3.49%
Dividend and dates
Avg Volume
31.28K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

GPAT Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+2.62%
2025+5.42%
2024 (partial year)+1.50%

As of September 4, 2026.

GPAT Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00$11.89M—
2024$0.00$8.67M—
2023$0.00−$14.04K—
2022$0.00−$30.84K—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$551.92K$11.89M—
2024$0.00—−$564.97K$8.67M—
2023$0.00—−$14.04K−$14.04K—
2022$0.00—−$30.84K−$30.84K—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

GPAT Valuation vs Shell Companies Median

Median of 587 stocks
MetricGPATShell Companies medianvs median
P/E43.8845.203% below
Profit margin0.00%0.00%0.0 pts above

Medians across 587 Shell Companies stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

The market values GP-Act III Acquisition Corp. (GPAT) at $177.29M. It is classified in the Shell Companies industry, within the Financial Services sector.

The most recent close on file for GPAT is $10.97, dated September 4, 2026. The close was unchanged from the previous session. Over the past 52 weeks the price has ranged from $10.56 to $12.00. The latest close sits 3.88% above that 52-week low.

Financial Health

In fiscal 2025, GP-Act III Acquisition Corp. reported revenue of $0.00. Net income for the same year was $11.89M. That is +37.13% against the prior fiscal year. Profit margin runs at 0%. Earnings per share on a trailing basis come to 0.25.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 2 report positive net income.

Valuation Assessment

The trailing P/E ratio stands at 43.88. That is 2.92% below the Shell Companies median of 45.2. 587 Shell Companies companies report these metrics, and the medians quoted come from that group.

Beta against the wider market is reported at −0. Daily returns over the trailing 2 years annualize to a volatility of 4.2%. Over the trailing twelve months the price has returned +3.49%. The stored price history starts on July 2, 2024, and the total return since then is +9.81%.

Growth & Income

The record shows no dividend for GPAT.

The record holds one complete calendar year, 2025, which returned +5.42%. 2026 is still running; the price is +2.62% year to date.

Peer Comparison

GP-Act III Acquisition Corp. (GPAT) operates in the Shell Companies industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
GP-Act III Acquisition Corp. GPAT $177.29M 43.9
Churchill Capital Corp XI CCXI $746.38M —
Churchill Capital Corp X CCCX $711.00M —
Drugs Made In America Acquisition II Corp. DMII $647.83M 35.1

The Shell Companies industry average P/E ratio is 45.2x. GP-Act III Acquisition Corp. trades at a P/E of 43.9.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Shell Companies Stocks

CCXI

Churchill Capital Corp XI

$746.38M

 CCCX

Churchill Capital Corp X

$711.00M

 DMII

Drugs Made In America Acquisition II Corp.

$647.83M

 BCSS

Bain Capital GSS Investment Corp.

$602.40M

 EVAC

EQV Ventures Acquisition Corp. II

$602.01M

 CXII

Churchill Capital Corp XII

$594.94M
View all Shell Companies stocks →

Popular Financial Services Stocks

BRK-B

Berkshire Hathaway Inc.

$1.08T

 JPM

JPMorgan Chase & Co.

$953.33B

 V

Visa Inc.

$700.27B

 MA

Mastercard Incorporated

$507.39B

 BAC

Bank of America Corporation

$438.31B
View all Financial Services stocks →

About GP-Act III Acquisition Corp.

GP-Act III Acquisition Corp. does not have significant operations. It focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was formerly known as GP Investments Acquisition Corp. II and changed its name to GP-Act III Acquisition Corp. in November 2020. GP-Act III Acquisition Corp. was incorporated in 2020 and is based in New York, New York.

Visit website →